Back to Clinical Trials

Brief Title: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Phase II/III Trial of Simmtecan and 5-FU/LV Regimen (FOLFSIM) Plus Teripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma

INTRODUCTION

  • Org Study ID: LP-201
  • Secondary ID: N/A
  • NTC ID: NCT03992911
  • Sponsor: Peking University

BRIEF SUMMARY


This study is designed as Phase II/III. Phase II is aimed to evaluate safety and efficacy of
Simmtecan and the 5-FU/LV regimen (FOLFSIM regimen) plus Toripalimab. Phase III is aimed to
verify inferiority of the overall survival of FOLFSIM regimen plus Toripalimab in comparison
with EP/EC in advanced or metastatic neuroendocrine cancer.

DETAILED DESCRIPTION


This is a Phase II/III, randomized, two-part, multi-center study, in which subjects with
advanced or metastatic neuroendocrine carcinoma will be enrolled.

This study will be conducted in two parts:

Part 1, the Phase II study was to: (i) evaluate the safety and tolerability of the FOLFSIM
regimen plus Toripalimab; and (ii) identify the recommended dose; (iii) assess the antitumor
activity; (iv) the pharmacokinetic (PK) parameters of the drugs in the regimen.

Part 2, the Phase III study was to verify inferiority of FOLFSIM regimen plus Toripalimab
compared with the current standard chemotherapy (EP/EC regimen) in the first-line treatment
of advanced or metastatic neuroendocrine carcinoma.


  • Overall Status
    Recruiting
  • Start Date
    June 19, 2019
  • Phase
    Phase 2/Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Overall survival

Primary Outcome 1 - Timeframe: 2 years

CONDITION

  • Neuroendocrine Carcinoma of the Bladder

ELIGIBILITY


Inclusion Criteria:

1. Signed informed-consent form.

2. Male and Female aged between 18-75 years.

3. Histologically confirmed locally advanced or metastatic nonfunctional
poorly-differentiated G3 neuroendocrine carcinoma(NEC), including small cell NEC,
large cell NEC and MANEC.

4. Unresectable, including local advanced, recurrent or metastatic disease:

Patients who had progressed after first-line platinum-based regimen or intolerance for
treatment, or unwilling to receive current standard chemotherapy (only for phase II);
Patients who has received no systemic chemotherapy, or relapsed at least 6 months
since completion of adjuvant chemotherapy or radiotherapy.

5. At least 1 measurable lesion according to RECIST criteria;

6. Providing with tumor specimen (for testing the expression of PD L1 and the
infiltrating lymphocytes);

7. Eastern Cooperative Oncology Group (ECOG) 0-1;

8. Adequate liver, kidney and bone marrow function; Screening laboratory values must meet
the following criteria: hemoglobin ≥ 10.0 g/dL; neutrophils ≥ 1500 cells/ μL;
platelets ≥ 100 x 10^3/ μL; total bilirubin ≤ 1.5 x upper limit of normal (ULN);
aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN without, and ≤
5 x ULN with hepatic metastasis; serum creatinine ≤1.5 x ULN, creatinine clearance
>60ml/min (CockcroftGault equation), INR≤1.5, APTT≤1.5 x ULN;

Exclusion Criteria:

1. Histologically confirmed well differentiated G3 neuroendocrine tumor;

2. Evidence with active CNS disease or epilepsy;

3. Metastasis over 5 lesions;

4. Prior treatment with CPT-11 or antiPD1/PDL1/CTLA-4 antibody for neoadjuvant or
adjuvant therapy;

5. Prior malignancy active within the previous 5 years except for locally curable cancers
that have been apparently cured, such as basal cell skin cancer or carcinoma in situ
of the cervix;

6. Predicted survival <3 months;

7. Severe, uncontrolled medical condition that would affect patients' compliance or
obscure the interpretation of toxicity determination or adverse events, including
active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure >
class II NYHA, heart block >II grade, myocardial infarction, unstable arrhythmia or
unstable angina within past 6 months, cerebral infarction within past 3 months) or
pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or
symptomatic bronchospasm);

8. Any uncontrollable active infection, within past 1 week

9. Patients with any active autoimmune disease or a documented history of autoimmune
disease, or history of syndrome that required systemic steroids or immunosuppressive
medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis,
hyperthyroidism or hypothyroidism;

10. History with tuberculosis;

11. The side effects caused by the previous treatment of the subjects did not return to
CTCAE ≤1; except hair loss and other tolerable events determined by investigator;

12. Hypersensitivity to Simmtecan or recombinant humanized antiPD1 monoclonal Ab or its
components;

13. Prior antitumor therapy (including chemotherapy, target therapy, corticosteroids and
immunotherapy) or participation in other clinical trials within past 4 weeks, or have
not recovered from toxicities since the last treatment;

14. Patients who received a potent inhibitor or inducer of CYP3A4 within 1 week prior to
the first dose;

15. Prior radical radiothearpy within past 4 weeks;

16. Prior major surgery within past 4 weeks (diagnostic surgery excluded);

17. Prior live vaccine therapy within past 4 weeks;

18. Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA
(>500IU/ml);

19. Pregnant or nursing;

20. Males or female of childbearing potential refuse to use using a reliable form of
contraception (eg, oral contraceptives, intrauterine device, control sex desire,
double barrier method of condom and spermicidal) during the treatment period and for
at least 12 months after the last dose of study drug.

21. Underlying medical condition that, in the Investigator's opinion, would increase the
risks of study drug administration or obscure the interpretation of toxicity
determination or adverse events.

Gender: All

Minimum Age: 75 Years

Maximum Age: 18 Years

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Lin Shen

Role: Principal Investigator

Affiliation: Peking University

Overall Contact

Name: Lin Shen

Phone: 86-10-88196561

Email: linshenpku@163.com

LOCATION

Facility Status Contact
Facility: Beijing Cancer Hospital
Beijing, Beijing 100142
China
Status: Recruiting Contact:
Shen Lin, Professor
010-88196561
Linshenpku@163.com